Alexion Pharmaceuticals can't suppress its enthusiasm for treating immune functions gone awry. The firm develops drugs that inhibit certain immune system functions that cause hematology, kidney, oncology, ophthalmology, and neurology disorders. The company's first marketed antibody product, Soliris, has won approval in the US, Canada, and some European and Asian countries for the treatment of two rare genetic and blood disorders known as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Alexion is also developing Soliris as a potential treatment for other autoimmune and inflammatory conditions, and it has development programs for other cancer-fighting antibodies.